A novel megakaryocyte potentiator produced by MC-1 human lung cancer cell line.
The hematopoietic stimulating activity of a human lung cancer cell line, MC-1, was investigated. The protein fraction (MC-1 protein) was prepared from the serum-free culture supernatant of MC-1 cells using hydroxyapatite and concanavalin A-agarose columns. In serum-containing cultures, MC-1 protein stimulated colony formation by megakaryocyte colony-forming units (CFU), erythroid burst-forming units and granulocyte/macrophage (GM) CFU. The stimulating effect was strongest for megakaryocyte CFU. The factor having megakaryocyte colony-stimulating activity was shown to be a protein whose molecular weight was determined to be 23,000 daltons by gel filtration. By various analyses, this protein was shown to be molecularly different from the heretofore-identified cytokines that may affect megakaryocytopoiesis, i.e., interleukin-1 (IL-1), IL-2, IL-3, IL-6, IL-7, IL-11, granulocyte colony-stimulating factor (CSF), macrophage CSF, GM-CSF, leukemia inhibitory factor, stem cell factor and tumor necrosis factor. Under serum-free conditions, MC-1 protein augmented murine megakaryocyte colony formation in the presence of murine IL-3 and increased the acetylcholinesterase activity of purified murine megakaryocytes. It was also shown that MC-1 protein stimulated human megakaryocyte colony formation. It was concluded that MC-1 cells produce a megakaryocyte potentiator which is molecularly different from any heretofore-identified cytokines.
Kuriya
S
S
Department of Medicine III, School of Medicine, Iwate Medical University, Morioka, Japan.
Ogata
K
K
An
E
E
Hamaguchi
H
H
Yokose
N
N
Anzai
Y
Y
Nomura
T
T
D000818:Animals; D002289:Carcinoma, Non-Small-Cell Lung / Q000737:chemistry / Q000378:metabolism* / Q000473:pathology*; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D003470:Culture Media / Q000032:analysis / Q000494:pharmacology; D016895:Culture Media, Serum-Free / Q000494:pharmacology; D016207:Cytokines / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D004912:Erythrocytes / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D006098:Granulocytes / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D006410:Hematopoiesis / Q000187:drug effects / Q000502:physiology; D016298:Hematopoietic Cell Growth Factors / Q000032:analysis / Q000378:metabolism* / Q000502:physiology*; D006801:Humans; D007377:Interleukin-3 / Q000494:pharmacology; D008175:Lung Neoplasms / Q000737:chemistry / Q000378:metabolism* / Q000473:pathology*; D008533:Megakaryocytes / Q000187:drug effects / Q000473:pathology* / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D009363:Neoplasm Proteins / Q000378:metabolism*; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D014407:Tumor Cells, Cultured
D003470:Culture Media; D016895:Culture Media, Serum-Free; D016207:Cytokines; D016298:Hematopoietic Cell Growth Factors; D007377:Interleukin-3; D009363:Neoplasm Proteins; D012333:RNA, Messenger